Review: Caloric restriction mimetics and autophagy signaling in the aging brain
This abstract-only review describes how rapamycin, metformin, resveratrol and spermidine act on the AMPK-mTOR-ULK1 axis to restore autophagic protein clearance in the aging brain; clinical use remains limited by poor brain bioavailability and missing human biomarkers. [1]
Automatic summary · not editorially reviewed
The key findings
The review describes brain aging as progressive failure of neuronal proteostasis with accumulation of toxic protein aggregates typical of Alzheimer's, Parkinson's and Huntington's diseases. [1]
Caloric restriction mimetics including rapamycin, metformin, resveratrol and spermidine are said to activate AMPK and suppress mTORC1, relieving ULK1 inhibition and promoting TFEB-driven lysosomal biogenesis. [1]
Preclinically these events are reported to enhance clearance of amyloid-β, tau, α-synuclein and mutant huntingtin and to improve mitophagy, while clinical translation is limited by poor CNS bioavailability and missing validated biomarkers. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Aging brain; preclinical models and proposed human translation, as described in the abstract
- Summary based on
- Study abstract
- Original publication
- October 5, 2026
Proteostasis failure and the AMPK-mTOR-autophagy hub
The review frames brain aging as a progressive failure of neuronal proteostasis, ending in accumulation of toxic protein aggregates typical of Alzheimer's, Parkinson's and Huntington's diseases. It presents the AMPK-mTOR-autophagy signaling hub as a link between cellular energy status and protein clearance machinery, and therefore as a therapeutic node. This is a conceptual framing in an abstract, not a measured result.
Supporting source [1]
Proposed dual AMPK activation and mTORC1 suppression
According to the abstract, caloric restriction mimetics such as rapamycin, metformin, resveratrol and spermidine activate AMPK through AMP/ATP modulation and at the same time suppress mTORC1 kinase activity. This dual action is said to relieve mTORC1-mediated inhibition of the ULK1 complex and trigger autophagosome nucleation, while sustained mTORC1 suppression promotes TFEB-driven lysosomal biogenesis. Together these events are described as restoring autophagic flux. These are proposed mechanisms, not demonstrated human outcomes.
Supporting source [1]
Preclinical clearance findings and translation barriers
Preclinically, the abstract states, these molecular events enhance clearance of amyloid-β, tau, α-synuclein and mutant huntingtin and improve mitochondrial quality control via mitophagy. Clinical translation is described as constrained by poor bioavailability in the central nervous system, context-dependent autophagic outcomes and the absence of validated pharmacodynamic biomarkers, such as LC3-II turnover and p62 flux, to confirm neuronal target engagement in humans. The review aims to provide a molecular framework for designing brain-penetrant formulations and combination and personalized strategies.
Supporting source [1]
How to interpret this
Only the abstract was reviewed; the full text was not reviewed. The abstract reports proposed mechanisms and preclinical findings without giving study designs, sample sizes, follow-up or human outcome data. No human lifespan or disease benefit is established.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Al-Jehani H, Al-Kuraishy HM, Abdelaziz AM, Mohamed AA, Mamdoh AM, Musa A, Mursy OMA, Batiha GE. · europepmc.org · October 5, 2026